Eiger Mountains

Investor Overview

Corporate Profile

Eiger is a late stage biopharmaceutical company focused on the development and commercialization of a pipeline of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs and for which no approved therapies exist.

The company’s lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection.  The company is rapidly advancing peginterferon lambda, a first-in-class interferon, toward registration for the treatment of HDV.  Eiger has initiated a rolling NDA submission for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies with plans to complete NDA submission and MAA submission in the first quarter of 2020.  For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary Eiger BioPharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
PALO ALTO, Calif. , Aug. 6, 2020 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for second quarter 2020 and provided a business update. 
Toggle Summary Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences
PALO ALTO, Calif. , Aug. 3, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in
Toggle Summary Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020
PALO ALTO, Calif. , May 29, 2020 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and
Toggle Summary Eiger to Present at Jefferies Virtual Healthcare Conference 2020
PALO ALTO, Calif. , May 26, 2020 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies
What's New
There are currently no items available.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site.